SCHEMBL1822935

SCHEMBL1822935

CCC(=O)Nc1ccc(OCc2ccc(Cl)c(F)c2)cc1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 2/20 0.47
HRH3 Q9Y5N1 1/20 0.46
KDM4E B2RXH2 4/20 0.45
ALDH1A1 P00352 3/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
PKM P14618 2/20 0.44
MAOB P27338 2/20 0.44
MAOA P21397 1/20 0.44
DVL1 O14640 1/20 0.43
CTSV O60911 1/20 0.43
CTSL P07711 1/20 0.43
PPARG P37231 1/20 0.43
MRGPRX4 Q96LA9 3/20 0.43
MAPK13 O15264 1/20 0.42
MAPK14 Q16539 1/20 0.42
DRD4 P21917 1/20 0.42
DRD3 P35462 1/20 0.42
SIGMAR1 Q99720 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4447374 0.97 MAOB (0.46) FFAR1HRH3KDM4EALDH1A1MEN1
SCHEMBL1825744 0.96 FFAR1 (0.49) FFAR1HRH3KDM4EALDH1A1MEN1
SCHEMBL1825736 0.91 TSHR (0.49) FFAR1KDM4EALDH1A1MEN1KMT2A
SCHEMBL1826956 0.90 MAOB (0.52) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL1826202 0.90 MAOB (0.53) FFAR1KDM4EALDH1A1MEN1KMT2A
SCHEMBL1825523 0.89 TSHR (0.49) FFAR1KDM4EALDH1A1MEN1KMT2A
SCHEMBL1824454 0.88 MRGPRX4 (0.53) FFAR1HRH3KDM4EALDH1A1MEN1
SCHEMBL1823119 0.87 KDM4E (0.45) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL1825707 0.87 THRA (0.49) FFAR1KDM4EALDH1A1MEN1KMT2A
SCHEMBL1824750 0.86 PTGDR2 (0.48) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461205-B2 Anthranilic acid derivatives CHELSEA THERAPEUTICS, INC. (US) 2013-06-11 US claimed
US-20120283326-A1 ANTHRANILIC ACID DERIVATIVES CHELSEA THERAPEUTICS, INC. 2012-11-08 US claimed
US-8263658-B2 Anthranilic acid derivatives CHELSEA THERAPEUTICS, INC. (US) 2012-09-11 US claimed
EP-2118051-B1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF CHELSEA THERAPEUTICS INC (US) 2011-05-04 EP claimed
US-20100029767-A1 ANTHRANILIC ACID DERIVATIVES Chelsea Therapeutics, Inc 2010-02-04 US claimed
US-8461205-B2 Anthranilic acid derivatives CHELSEA THERAPEUTICS, INC. (US) 2013-06-11 US disclosed
US-20120283326-A1 ANTHRANILIC ACID DERIVATIVES CHELSEA THERAPEUTICS, INC. 2012-11-08 US disclosed
US-8263658-B2 Anthranilic acid derivatives CHELSEA THERAPEUTICS, INC. (US) 2012-09-11 US disclosed
EP-2118051-B1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF CHELSEA THERAPEUTICS INC (US) 2011-05-04 EP disclosed
US-20100029767-A1 ANTHRANILIC ACID DERIVATIVES Chelsea Therapeutics, Inc 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283326-A1 ANTHRANILIC ACID DERIVATIVES ACOX3, BCL3, AOC3 FFAR1 873/4885HRH3 103/4885KDM4E 4207/4885
US-20100029767-A1 ANTHRANILIC ACID DERIVATIVES ACOX3, BCL3, AOC3 FFAR1 878/4885HRH3 107/4885KDM4E 4172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.